Aurinia settles with Teva, helping stave off potential Lupkynis generic until late 2036
Aurinia Pharmaceuticals settled a patent dispute with Teva, delaying a generic version of Lupkynis until 2036. The deal assumes Teva's FDA approval and keeps Aurinia's market protection. Shares rose 7%. Aurinia faces ongoing litigation with other generics makers. Lupkynis is its only marketed drug, with H1 2024 revenue up 21% YoY.
How this was made
The 30-second read
Why it matters
The settlement removes immediate generic threat, likely sustaining current price momentum.
Market read
First‑report settlement news with material impact on Aurinia's valuation and sector dynamics.
What to watch
Pending litigation with other generics (DifGen, Dr. Reddy’s, etc.) could still erode market share.
Background
Aurinia's Lupkynis is its only marketed drug; protecting its patent life is critical for revenue.
Ticker impact
Aurinia settled with Teva, extending Lupkynis generic protection until Dec 2036, driving a 7% share rise.
Potential upside of 5‑10% over the next weeks as investors price in extended exclusivity.
Extended patent protection is material for Aurinia's sole product, reducing dilution risk and improving revenue outlook.
Market effects
Strengthens the lupus therapeutic niche, may pressure peers GSK, Roche, AstraZeneca on pricing.
U.S. biotech sector gains confidence from reinforced IP enforcement.
Limited to companies with similar biologic exclusivity concerns.
Counterpoint
If Teva secures FDA approval quickly, the settlement could be short‑lived, limiting upside.
Key entities
- companyAurinia Pharmaceuticals
U.S. biotech focused on lupus drug Lupkynis.
- companyTeva Pharmaceuticals
Generic drug maker seeking to launch a voclosporin generic.
